Liquid Biopsy Market Worth 2.04 Million Usd By 2022

By Author: MarketsandMarkets
Total Articles: 341
Comment this article

According to a new market research report Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%. The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

Browse 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Liquid Biopsy Market"

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
...
...
By product, the assay kits segment is expected to account for the largest share of the market in 2017

On the basis of product, the Liquid Biopsy Market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.

By circulating biomarkers, circulating tumor cells is expected to account for the largest market share in 2017

Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the circulating tumor cells segment is expected to account for the largest share of the Liquid Biopsy Market. The ability for early assessment of patient prognosis and also providing valuable information to make a clinical decision is driving the growth of the CTC segment in the Liquid Biopsy Market.

By clinical application, the therapy selection segment is expected to account for the largest market share in 2017

Based on clinical application, the Liquid Biopsy Market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the Liquid Biopsy Market in 2017. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in detection of early-stage cancers.

By application, the cancer segment is expected to account for the largest market share in 2017

Based on application, the Liquid Biopsy Market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). In 2017, cancer applications segment is expected to account for the largest share of the Liquid Biopsy Market. Increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications is driving the growth of this market.

By end user, the reference laboratories segment is expected to account for the largest market share in 2017

Based on end user, the Liquid Biopsy Market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the Liquid Biopsy Market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories.

North America is expected to dominate the market in 2017

North America is expected to account for the largest share of the Liquid Biopsy Market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.

Request For Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

The key players in the global Liquid Biopsy Market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

An innovative professional with 6+ years of progressive experience within the Healthcare industry. with the skills to drive business growth, capitalize on new revenue potential, and manage all aspects of daily internet / eCommerce operations.